Login
$VYGR
$1.63 -$0.10 (5.78%) Live

$VYGR SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
05 Nov 2026 8-K: Completion of Acquisition or Disposition of Assets

- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -

05 Nov 2026 10-Q
03 Nov 2026 Form 4: Carter Todd Alfred, Chief Scientific Officer

Received 33,000 shares as a grant or award · Granted 154,000 Stock Option (Right to Buy)

03 Nov 2026 Form 4: Swartz Robin, President

Received 68,250 shares as a grant or award · Granted 318,500 Stock Option (Right to Buy)

21 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Amended and Restated Employment Agreement (this “Agreement”) is made as of October 20, 2026 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Robin Swartz (the “Executive”).

14 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 8-K: Results of Operations and Financial Condition

- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -

06 Aug 2026 10-Q
31 Jul 2026 SCHEDULE 13G/A
13 Jul 2026 8-K: Other Events

On July 13, 2026, Voyager Therapeutics, Inc. (the “Company”) presented good laboratory practice (“GLP”) toxicology data for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellu...

11 Jun 2026 Form 4: Scangos George A, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Mackey Catherine J, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Hyman Steven, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Vitale Nancy, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Higgins Michael J, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Onyia Jude, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Geraghty James A, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Colon Grace, Director

Granted 30,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Pierce Glenn, Director

Granted 30,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support